Natpara approved for hormone disorder causing low blood calcium

(HealthDay)—Natpara (parathyroid hormone) has been approved by the U.S. Food and Drug Administration to control low blood calcium among people with hypoparathyroidism.

Hypoparathyroidism is a rare disease that occurs when the body doesn't secrete enough , which regulates blood levels of calcium and phosphorus.

Hypoparathyroidism is typically caused by malfunctioning or surgically removed . The condition affects about 60,000 people in the United States, the FDA said in a news release. Symptoms commonly include numbness, tingling, muscle twitching, cramps, and seizures. Longer-term complications may include kidney damage, kidney stones and cataracts.

Natpara, a once-daily injection, was evaluated in a clinical study of 124 people. Forty-two percent of those treated with Natpara achieved normal blood calcium levels, the FDA said.

The drug's label includes a boxed warning that had been observed in a study of rats given Natpara. However, it's unknown if the drug would cause bone cancer among people, the FDA said.

The most common side effects of Natpara include tingling, pricking and burning of the skin, low blood calcium, headache, high blood calcium and nausea.

Natpara is produced by NPS Pharmaceuticals, based in Bedminster, N.J.

Explore further

Shire to buy specialty drugmaker NPS Pharma for $5.2 billion

More information: Learn more by visiting the FDA.

Copyright © 2015 HealthDay. All rights reserved.

Citation: Natpara approved for hormone disorder causing low blood calcium (2015, January 26) retrieved 23 July 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments